Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dolby Laboratories (DLB) Short-term Investments (2016 - 2025)

Dolby Laboratories (DLB) has disclosed Short-term Investments for 17 consecutive years, with $739000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Short-term Investments changed N/A year-over-year to $739000.0, compared with a TTM value of $739000.0 through Dec 2025, changed N/A, and an annual FY2025 reading of $703000.0, changed N/A over the prior year.
  • Short-term Investments was $739000.0 for Q4 2025 at Dolby Laboratories, up from $703000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $189.2 million in Q3 2022 and bottomed at $703000.0 in Q3 2025.
  • Average Short-term Investments over 5 years is $97.8 million, with a median of $125.3 million recorded in 2023.
  • The sharpest move saw Short-term Investments skyrocketed 387.17% in 2022, then plummeted 99.4% in 2025.
  • Year by year, Short-term Investments stood at $80.6 million in 2021, then skyrocketed by 64.82% to $132.9 million in 2022, then rose by 5.98% to $140.8 million in 2023, then fell by 9.59% to $127.3 million in 2024, then tumbled by 99.42% to $739000.0 in 2025.
  • Business Quant data shows Short-term Investments for DLB at $739000.0 in Q4 2025, $703000.0 in Q3 2025, and $763000.0 in Q2 2025.